Stock Events

Willow Biosciences 

C$0.09
14
+C$0+0% Tuesday 18:20

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
13.7M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

13
NOV
Earnings
 

Earnings

13NovExpected
Q3 2021
Q1 2022
Q2 2022
Q3 2022
Q1 2024
Q2 2024
Next
-0.02
-0.01
0.01
0.02
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow WLLW.TO. It's not an investment recommendation.
Alphabet
79412
GOOGL
Apple
69108
AAPL
Microsoft
64535
MSFT
Amazon
60167
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap4.06B
CRISPR Therapeutics is involved in gene editing, a technology that can be seen as complementary or competitive to biosynthesis in developing therapeutic products.
Editas Medicine
EDIT
Mkt Cap308.46M
Editas Medicine operates in the genome editing field, which competes with biosynthesis for applications in medicine and agriculture.
Intellia Therapeutics
NTLA
Mkt Cap2.28B
Intellia Therapeutics is another key player in the CRISPR space, potentially competing with Willow in the development of novel therapeutics.
Evogene
EVGN
Mkt Cap18.45M
Evogene utilizes computational biology to improve product development in agriculture, which could compete with Willow's biosynthetic approaches in the same sector.
Synlogic
SYBX
Mkt Cap17.31M
Synlogic operates in synthetic biology, using engineered bacteria for therapeutic purposes, which is a direct competitor to Willow's biosynthesis technologies.
Adaptive Biotechnologies
ADPT
Mkt Cap693.12M
Adaptive Biotechnologies focuses on the immune-driven discovery and development of therapeutics, potentially competing in the biotech space with Willow.
Twist Bioscience
TWST
Mkt Cap2.53B
Twist Bioscience specializes in synthetic DNA production, which is foundational for biosynthesis and directly competes with Willow's technology platform.
Co-Diagnostics
CODX
Mkt Cap44.36M
Co-Diagnostics uses molecular diagnostics for detection of DNA or RNA, which can be seen as a competing technology for applications targeted by Willow's biosynthesis.
Pacific Biosciences of California
PACB
Mkt Cap373.36M
Pacific Biosciences offers sequencing technologies that, while not directly competitive, are part of the broader biotech ecosystem that intersects with Willow's market.

About

Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical products in the United States. The company has a collaboration agreement with SUANFARMA to develop anti-infective API through precision fermentation; and a multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients. Willow Biosciences Inc. was founded in 2019 and is headquartered in Calgary, Canada.
Show more...
CEO
Mr. Travis Doupe
Employees
19
Country
CA
ISIN
CA97111B4047

Listings

CN
CA
WLLW.CN
TO
CA
WLLW.TO
US
CANSF
F
DE
3D7.F